Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Amir Jazeri, MD
CONTACT
Lead
M.D. Anderson Cancer Center
With
Primary Objectives: To estimate disease control rate (DCR) in patients with metastatic, recurrent, or persistent cervical cancer who have not received prior systemic chemotherapy and are undergoing induction immunotherapy with MGD019. Secondary Objectives: 1. To determine overall survival (OS) 2. To determine progression-free survival (PFS) 3. To determine objective response rate (ORR) 4. To determine duration of response (DOR) 5. To evaluate safety of administering MGD019 in cervical cancer patients using the National Institute of Health Common Terminology Criteria for Adverse Events (CTCAE) v5.0 Exploratory Objectives: 1. To investigate molecular and immunological changes in the tumor tissue prior to and on-treatment with MGD019 2. To identify treatment-induced tissue-based alterations in malignant and immune cells and their correlation with response, progression, and immune-related adverse events 3. To determine the utility of cell-free DNA for evaluation treatment response
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted